MCRB Key Statistics, Chart & Performance
The current stock price of MCRB is 15.65 USD. In the past month the price decreased by -7.83%. In the past year, price decreased by -7.32%.
MCRB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About MCRB
Company Profile
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2015-06-26. The company is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Company Info
SERES THERAPEUTICS INC
101 Cambridge Park Drive
Cambridge MASSACHUSETTS 02139 US
CEO: Eric D. Shaff
Employees: 103
Phone: 16179459626
SERES THERAPEUTICS INC / MCRB FAQ
What does SERES THERAPEUTICS INC do?
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2015-06-26. The company is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
What is the current price of MCRB stock?
The current stock price of MCRB is 15.65 USD. The price increased by 1.29% in the last trading session.
Does MCRB stock pay dividends?
MCRB does not pay a dividend.
How is the ChartMill rating for SERES THERAPEUTICS INC?
MCRB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of SERES THERAPEUTICS INC (MCRB)?
SERES THERAPEUTICS INC (MCRB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.29).
Can you provide the number of employees for SERES THERAPEUTICS INC?
SERES THERAPEUTICS INC (MCRB) currently has 103 employees.
Who owns SERES THERAPEUTICS INC?
You can find the ownership structure of SERES THERAPEUTICS INC (MCRB) on the Ownership tab.
MCRB Technical Analysis
MCRB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MCRB. The financial health of MCRB is average, but there are quite some concerns on its profitability.
MCRB Financial Highlights
Over the last trailing twelve months MCRB reported a non-GAAP Earnings per Share(EPS) of -6.29. The EPS increased by 73.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1536.75% | ||
| ROA | 3.76% | ||
| ROE | 12.34% | ||
| Debt/Equity | 0 |
MCRB Forecast & Estimates
9 analysts have analysed MCRB and the average price target is 21.42 USD. This implies a price increase of 36.87% is expected in the next year compared to the current price of 15.65.